Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PVLA - US6979471090 - Common Stock

88.44 USD
-11.84 (-11.81%)
Last: 1/5/2026, 8:00:00 PM
Fundamental Rating

3

Overall PVLA gets a fundamental rating of 3 out of 10. We evaluated PVLA against 530 industry peers in the Biotechnology industry. While PVLA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PVLA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PVLA has reported negative net income.
In the past year PVLA has reported a negative cash flow from operations.
In the past 5 years PVLA always reported negative net income.
In the past 5 years PVLA always reported negative operating cash flow.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

The Return On Assets of PVLA (-51.84%) is comparable to the rest of the industry.
With a Return On Equity value of -89.05%, PVLA perfoms like the industry average, outperforming 49.43% of the companies in the same industry.
Industry RankSector Rank
ROA -51.84%
ROE -89.05%
ROIC N/A
ROA(3y)-39.21%
ROA(5y)-36.57%
ROE(3y)-79.28%
ROE(5y)-89.59%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PVLA has been increased compared to 1 year ago.
PVLA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PVLA has a worse debt to assets ratio.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

PVLA has an Altman-Z score of 19.48. This indicates that PVLA is financially healthy and has little risk of bankruptcy at the moment.
PVLA has a Altman-Z score of 19.48. This is amongst the best in the industry. PVLA outperforms 88.87% of its industry peers.
PVLA has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.41, PVLA is doing worse than 69.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 19.48
ROIC/WACCN/A
WACC8.83%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

PVLA has a Current Ratio of 6.70. This indicates that PVLA is financially healthy and has no problem in meeting its short term obligations.
PVLA's Current ratio of 6.70 is fine compared to the rest of the industry. PVLA outperforms 68.30% of its industry peers.
A Quick Ratio of 6.70 indicates that PVLA has no problem at all paying its short term obligations.
PVLA's Quick ratio of 6.70 is fine compared to the rest of the industry. PVLA outperforms 68.49% of its industry peers.
Industry RankSector Rank
Current Ratio 6.7
Quick Ratio 6.7
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.54%, which is quite impressive.
Looking at the last year, PVLA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)73.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PVLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.88% yearly.
Based on estimates for the next years, PVLA will show a very strong growth in Revenue. The Revenue will grow by 586.68% on average per year.
EPS Next Y-16.58%
EPS Next 2Y-13.6%
EPS Next 3Y-24.91%
EPS Next 5Y24.88%
Revenue Next Year-100%
Revenue Next 2Y50.53%
Revenue Next 3Y898.04%
Revenue Next 5Y586.68%

3.3 Evolution

PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PVLA. In the last year negative earnings were reported.
Also next year PVLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as PVLA's earnings are expected to decrease with -24.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.6%
EPS Next 3Y-24.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PVLA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (1/5/2026, 8:00:00 PM)

88.44

-11.84 (-11.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners64.74%
Inst Owner Change0%
Ins Owners16.63%
Ins Owner Change0%
Market Cap1.05B
Revenue(TTM)N/A
Net Income(TTM)-34.73M
Analysts84.44
Price Target178.5 (101.83%)
Short Float %10.07%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.13%
Min EPS beat(2)-20.45%
Max EPS beat(2)-13.81%
EPS beat(4)1
Avg EPS beat(4)-76.9%
Min EPS beat(4)-313.44%
Max EPS beat(4)40.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)54.34%
PT rev (3m)167.34%
EPS NQ rev (1m)-0.99%
EPS NQ rev (3m)-8.94%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)-6.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 26.85
P/tB 26.85
EV/EBITDA N/A
EPS(TTM)-5.35
EYN/A
EPS(NY)-3.95
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.84%
ROE -89.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.21%
ROA(5y)-36.57%
ROE(3y)-79.28%
ROE(5y)-89.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.7
Quick Ratio 6.7
Altman-Z 19.48
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.62%
EPS Next Y-16.58%
EPS Next 2Y-13.6%
EPS Next 3Y-24.91%
EPS Next 5Y24.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y50.53%
Revenue Next 3Y898.04%
Revenue Next 5Y586.68%
EBIT growth 1Y-42.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.82%
EBIT Next 3Y-80.23%
EBIT Next 5Y36.37%
FCF growth 1Y52.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.85%
OCF growth 3YN/A
OCF growth 5YN/A

PALVELLA THERAPEUTICS INC / PVLA FAQ

What is the ChartMill fundamental rating of PALVELLA THERAPEUTICS INC (PVLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PVLA.


What is the valuation status for PVLA stock?

ChartMill assigns a valuation rating of 0 / 10 to PALVELLA THERAPEUTICS INC (PVLA). This can be considered as Overvalued.


How profitable is PALVELLA THERAPEUTICS INC (PVLA) stock?

PALVELLA THERAPEUTICS INC (PVLA) has a profitability rating of 1 / 10.